Rabbit polyclonal antibody against human urokinase-type plasminogen activator (uPA / PLAU; abbokinase), affinity-purified on immobilised human urokinase and cross-adsorbed against plasma proteins, 0.5 mg. Pan-form neutralising reagent — recognises HMW single-chain (54 kDa), HMW two-chain (52 kDa) and LMW (33 kDa) uPA and completely inhibits uPA-catalysed plasminogen activation and S2444 cleavage, with no cross-reactivity to tPA, plasmin, trypsin, chymotrypsin, elastase or thrombin. For uPA ELISA, IHC, Western blot, immunoprecipitation and function-blocking studies — the polyclonal companion to the uPA monoclonals cat. 335 (clone PGM2005) and cat. 381 (clone PGM2001).
SPECIFICATIONS
Catalogue number: 168 | Host: Rabbit | Target: Human
Target antigen: Urokinase-type plasminogen activator (uPA / PLAU; abbokinase)
Gene: PLAU (10q24.33) | UniProt: P00749
Clonality: Polyclonal | Conjugate: Unconjugated
Isoform reactivity: HMW single-chain uPA (54 kDa), HMW two-chain uPA (52 kDa), LMW uPA (33 kDa)
Specificity: Recognises all uPA forms; no cross-reactivity to tPA, plasmin, trypsin, chymotrypsin, elastase or thrombin; no interference from human plasma. Neutralising — completely inhibits uPA-catalysed plasminogen activation and S2444 cleavage (affinity Kd ~0.1 nM).
Purification: Affinity-purified on immobilised human urokinase, cross-adsorbed on immobilised human plasma proteins.
Format: Lyophilised from 0.01 M Na phosphate, 0.01 M Na borate, 0.15 M NaCl, 1% dextran, 1% mannitol, pH 8 | Package size: 0.5 mg (reconstitute in 1 mL water)
STORAGE / RECONSTITUTION
Reconstitute with 1 mL sterile pure water. Ships at ambient temperature. Store lyophilised antibody 2 years at -20 °C or lower; store reconstituted antibody at +4 °C up to 4 weeks, or aliquot and freeze at -20 °C. Avoid repeated freeze-thaw.
APPLICATIONS
- ELISA — detection of human uPA (dilution 1:5 000).
- IHC (FFPE / frozen sections) — uPA in tumour invasive fronts and peri-tumoural stroma (breast, colorectal and other carcinomas); starting dilution 1:50.
- Western blot — 1:1 000 to 1:5 000; detects HMW-scuPA (54 kDa), HMW-tcuPA (52 kDa) and LMW-uPA (33 kDa).
- Immunoprecipitation — protein A / G beads, 1–5 µg antibody per 100–500 µL sample (plasma, urine, conditioned medium).
- Functional neutralisation / function-blocking — titrate in molar excess vs uPA; blocks uPA-catalysed plasminogen activation in cancer-cell invasion (transwell, Matrigel, 3-D spheroid) and ECM-degradation assays.
APPLICATION HIGHLIGHTS — HIGH-VALUE RESEARCH NICHES
- Cancer prognostic-biomarker IHC — uPA in tumour invasive fronts and peri-tumoural stroma.
- Cancer invasion / metastasis research — pan-form reactivity combined with neutralising activity.
- Fibrinolysis and thrombosis research — selective uPA neutralisation without tPA / plasmin cross-blocking.
- Atherosclerosis and vascular biology — uPA IHC of atherosclerotic plaques and plaque macrophages.
- Glomerulonephritis / kidney disease — uPA IHC of glomerular epithelium and podocytes.
- Inflammation and neutrophil biology — neutrophil-derived uPA quantification in inflamed tissue.
- Wound-healing and keratinocyte migration — uPA blockade in keratinocyte and fibroblast migration assays.
- uPA / uPAR / PAI-1 axis pharmacology — component of pre-clinical inhibitor screens.
